Eli Lilly (NYSE:LLY) announced that it will integrate Dexcom (NSDQ:DXCM) products into its personalized diabetes management system, now under development.
Under the new, non-exclusive agreement, Indianapolis-based Lilly will use San Diego-based Dexcom’s continuous glucose monitoring (CGM) devices in pen-based and pump-based platforms in Lily’s diabetes management system.
The pen-based platform is designed to integrate personalized data from a pre-filled, disposable insulin pen with data from glucose-sensing technology, while the pump-based platform, a hybrid closed-loop system, is designed to automate insulin dosing through the integration of an insulin pump, CGM and handheld controller or smartphone application.
Get the full story at our sister site, Drug Delivery Business News.